Urotensin II-induced insulin resistance is mediated by NADPH oxidase-derived reactive oxygen species in HepG2 cells

World J Gastroenterol. 2016 Jul 7;22(25):5769-79. doi: 10.3748/wjg.v22.i25.5769.

Abstract

Aim: To investigated the effects of urotensin II (UII) on hepatic insulin resistance in HepG2 cells and the potential mechanisms involved.

Methods: Human hepatoma HepG2 cells were cultured with or without exogenous UII for 24 h, in the presence or absence of 100 nmol/L insulin for the last 30 min. Glucose levels were detected by the glucose-oxidase method and glycogen synthesis was analyzed by glycogen colorimetric/fluorometric assay. Reactive oxygen species (ROS) levels were detected with a multimode reader using a 2',7'-dichlorofluorescein diacetate probe. The protein expression and phosphorylation levels of c-Jun N-terminal kinase (JNK), insulin signal essential molecules such as insulin receptor substrate -1 (IRS-1), protein kinase B (Akt), glycogen synthase kinase-3β (GSK-3β), and glucose transporter-2 (Glut 2), and NADPH oxidase subunits such as gp91(phox), p67(phox), p47(phox), p40(phox), and p22(phox) were evaluated by Western blot.

Results: Exposure to 100 nmol/L UII reduced the insulin-induced glucose consumption (P < 0.05) and glycogen content (P < 0.01) in HepG2 cells compared with cells without UII. UII also abolished insulin-stimulated protein expression (P < 0.01) and phosphorylation of IRS-1 (P < 0.05), associated with down-regulation of Akt (P < 0.05) and GSK-3β (P < 0.05) phosphorylation levels, and the expression of Glut 2 (P < 0.001), indicating an insulin-resistance state in HepG2 cells. Furthermore, UII enhanced the phosphorylation of JNK (P < 0.05), while the activity of JNK, insulin signaling, such as total protein of IRS-1 (P < 0.001), phosphorylation of IRS-1 (P < 0.001) and GSK-3β (P < 0.05), and glycogen synthesis (P < 0.001) could be reversed by pretreatment with the JNK inhibitor SP600125. Besides, UII markedly improved ROS generation (P < 0.05) and NADPH oxidase subunit expression (P < 0.05). However, the antioxidant/NADPH oxidase inhibitor apocynin could decrease UII-induced ROS production (P < 0.05), JNK phosphorylation (P < 0.05), and insulin resistance (P < 0.05) in HepG2 cells.

Conclusion: UII induces insulin resistance, and this can be reversed by JNK inhibitor SP600125 and antioxidant/NADPH oxidase inhibitor apocynin targeting the insulin signaling pathway in HepG2 cells.

Keywords: HepG2 cells; Insulin resistance; NADPH oxidase; Reactive oxygen species; Urotensin II.

MeSH terms

  • Acetophenones / pharmacology
  • Blotting, Western
  • Down-Regulation
  • Enzyme Inhibitors / pharmacology
  • Glucose / metabolism
  • Glucose Transporter Type 2 / drug effects
  • Glucose Transporter Type 2 / metabolism
  • Glycogen / biosynthesis
  • Glycogen Synthase Kinase 3 beta / drug effects
  • Glycogen Synthase Kinase 3 beta / metabolism
  • Hep G2 Cells
  • Humans
  • Hypoglycemic Agents / pharmacology
  • Insulin / pharmacology
  • Insulin Receptor Substrate Proteins / drug effects
  • Insulin Receptor Substrate Proteins / metabolism
  • Insulin Resistance*
  • MAP Kinase Kinase 4 / drug effects
  • MAP Kinase Kinase 4 / metabolism
  • NADPH Oxidases / drug effects*
  • NADPH Oxidases / metabolism
  • Phosphorylation / drug effects
  • Proto-Oncogene Proteins c-akt / drug effects
  • Proto-Oncogene Proteins c-akt / metabolism
  • Reactive Oxygen Species / metabolism*
  • Urotensins / pharmacology*

Substances

  • Acetophenones
  • Enzyme Inhibitors
  • Glucose Transporter Type 2
  • Hypoglycemic Agents
  • IRS1 protein, human
  • Insulin
  • Insulin Receptor Substrate Proteins
  • Reactive Oxygen Species
  • SLC2A2 protein, human
  • Urotensins
  • Glycogen
  • urotensin II
  • acetovanillone
  • NADPH Oxidases
  • Glycogen Synthase Kinase 3 beta
  • Proto-Oncogene Proteins c-akt
  • MAP Kinase Kinase 4
  • Glucose